+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)

Results for tag: "Dermatophytic Onychomycosis Drug"

From
From
From
Dermatophytic Onychomycosis - Epidemiology Forecast to 2032 - Product Thumbnail Image

Dermatophytic Onychomycosis - Epidemiology Forecast to 2032

  • Report
  • January 2022
  • 60 Pages
  • Global
From
Dermatophytic Onychomycosis: US Drug Forecast and Market Analysis to 2028 - Product Thumbnail Image

Dermatophytic Onychomycosis: US Drug Forecast and Market Analysis to 2028

  • Report
  • January 2020
  • 76 Pages
  • United States
From
Dermatophytic Onychomycosis: Epidemiology Forecast to 2028 - Product Thumbnail Image

Dermatophytic Onychomycosis: Epidemiology Forecast to 2028

  • Report
  • January 2020
  • 18 Pages
  • Global
From
  • 9 Results (Page 1 of 1)
Loading Indicator

Dermatophytic Onychomycosis (DO) is a fungal infection of the nail caused by dermatophytes. It is the most common type of onychomycosis, accounting for up to 50% of all nail infections. Treatment of DO typically involves the use of antifungal drugs, such as terbinafine, itraconazole, and fluconazole. These drugs are typically administered orally or topically, depending on the severity of the infection. Infectious Diseases Drugs are a class of drugs used to treat a wide range of infectious diseases, including DO. These drugs are typically prescribed by a physician and are available in both generic and brand-name formulations. Commonly prescribed Infectious Diseases Drugs include antibiotics, antivirals, antifungals, and antiparasitics. Some companies in the Dermatophytic Onychomycosis Drug market include Pfizer, Merck, Novartis, and Johnson & Johnson. Show Less Read more